RVPH: Brilaroxazine's phase III data show strong efficacy, safety, and plans for NDA filing by 2028Quartr·Sep 29, 2026 at 09:36 PMRVPH+2.00%
Reviva to Participate in the Lytham Partners Fall 2026 Investor ConferenceUnusual Whales·Sep 22, 2026 at 12:02 PMRVPH+2.00%
The Market's Odd-Lot Bin: What 10 Niche Tickers Tell Us About 2026Global Report·Aug 18, 2026 at 10:12 AMFWD+0.60%CDLX+9.09%
OTC Market Listing Exposes Reviva Pharmaceuticals to Volatility, Illiquidity and Pricing RisksTip Ranks·Aug 14, 2026 at 06:00 AMRVPH+2.00%
Reviva Q2 FY26 net loss narrows to $2.4 million; cash climbs to $19.9 million as of June 30, 2026PUBT·Aug 12, 2026 at 08:29 PMRVPH+2.00%
Delisting of Securities from The Nasdaq Stock Market | NDAQ Stock NewsStockTitan·Jul 10, 2026 at 08:00 AMBTM0.00%BOWN0.00%
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·May 13, 2026 at 05:06 PMRVPH+2.00%REPL+0.61%
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights | RVPH Stock NewsStockTitan·May 13, 2026 at 12:35 PMRVPH+2.00%SBIO+0.20%
Reviva Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 EPS results.benzinga_article·Mar 30, 2026 at 02:45 PMPBE+2.07%IBB+1.30%
